Blood cancer drug pirtobrutinib tested for Long-Term safety in ongoing study

NCT ID NCT06876662

Recruiting now Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) who were already in a previous trial. About 279 participants will continue their treatment or follow-up visits. The main goal is to track serious side effects and overall survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

CHU de Nantes - Hotel Dieu
RECRUITING

Nantes, 44093, France
Cayuga Cancer Center
ACTIVE_NOT_RECRUITING

Ithaca, New York, 14850, United States
Churchill Hospital
RECRUITING

Oxford, OX3 7LE, United Kingdom
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States
Derriford Hospital
RECRUITING

Plymouth, PL6 8DH, United Kingdom
Duke University Medical Center
RECRUITING

Durham, North Carolina, 27710-4000, United States
Flinders Medical Centre
RECRUITING

Adelaide, 5042, Australia
Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232-6422, United States
Hokkaido University Hospital
ACTIVE_NOT_RECRUITING

Sapporo, 060-8648, Japan
IRCCS-AOU di Bologna-Policlinico S.Orsola-Malpighi
COMPLETED

Bologna, 40138, Italy
Instytut Hermatologii I Transfuzjologii
RECRUITING

Warsaw, 02-776, Poland
Linear Clinical Research
ACTIVE_NOT_RECRUITING

Victoria, 3000, Australia
Mayo Clinic- Minnesota
RECRUITING

Rochester, Minnesota, 55905, United States
Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226-3548, United States
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
RECRUITING

New York, New York, 10065-6007, United States
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
ACTIVE_NOT_RECRUITING

New York, New York, 10065-6007, United States
Nagoya Medical Center
ACTIVE_NOT_RECRUITING

Aichi-Ken, 4600001, Japan
National Cancer Center Hospital
COMPLETED

Cho-ku, 104-0045, Japan
National Hospital Organization Kyushu Cancer Center
ACTIVE_NOT_RECRUITING

Fukuoka, 811-1395, Japan
Northwell Health
RECRUITING

Lake Success, New York, 11042-1118, United States
Northwestern University
RECRUITING

Chicago, Illinois, 60611-3013, United States
Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210-1063, United States
Ospedale San Raffaele
RECRUITING

Milan, 20132, Italy
Peter MacCallum Cancer Centre
COMPLETED

Melbourne, 3000, Australia
Pratia MCM Krakow
RECRUITING

Krakow, 30727, Poland
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
St James's University Hospital
RECRUITING

Leeds, LS9 7TF, United Kingdom
Swedish Cancer Institute
RECRUITING

Seattle, Washington, 98104-3588, United States
Sylvester Comprehensive Cancer Center
RECRUITING

Miami, Florida, 33136-1002, United States
Tennessee Oncology
RECRUITING

Nashville, Tennessee, 37203-2659, United States
The Emory Clinic
RECRUITING

Atlanta, Georgia, 30322-1013, United States
Tohoku University Hospital
ACTIVE_NOT_RECRUITING

Miyagi-Ken, 9808574, Japan
Tokai University Hospital- Isehara Campus
ACTIVE_NOT_RECRUITING

Isehara, 259-1193, Japan
University Of Nebraska Medical Center
RECRUITING

Omaha, Nebraska, 69198, United States
University of Pennsylvania Hospital
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030-4000, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.